Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.

Pan-Petesch, B; Laguna, P; Mital, A; Stanley, J; Torchet, M F; Salek, S Z; Salaj, P

Pan-Petesch, B; Laguna, P; Mital, A; Stanley, J; Torchet, M F; Salek, S Z; Salaj, P.

Affiliation

Pan-Petesch B; Centre Régional de Traitement de l'Hémophilie et des Maladies Hémorragiques, CHU de Brest, France. brigitte.pan-petesch@chu-brest.fr

Haemophilia ; 15(3): 760-5, 2009 May.

Article in En | MEDLINE | ID: mdl-19298382

Subject(s)

Blood Coagulation Factor Inhibitors/administration & dosage; Factor VIIa/administration & dosage; Hemarthrosis/drug therapy; Hemophilia A/drug therapy; Hemostasis/drug effects; Adult; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Hemarthrosis/prevention & control; Hemophilia A/complications; Humans; Infant; Male; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Factor VIIa / Blood Coagulation Factor Inhibitors / Hemarthrosis / Hemophilia A / Hemostasis Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Adult / Child / Humans / Infant / Male Country/Region as subject: Europa Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2009 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google